160 results match your criteria: "National Centre for Asbestos Related Diseases[Affiliation]"

Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma.

View Article and Find Full Text PDF

Mesothelioma is a lethal cancer. Despite promising outcomes associated with immunotherapy, durable responses remain restricted to a minority of patients, highlighting the need for improved strategies that better predict outcome. Here, we described the development of a mesothelioma-specific gene signature that accurately predicts survival.

View Article and Find Full Text PDF

Stem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma.

Transl Lung Cancer Res

September 2024

National Centre for Asbestos Related Diseases, Faculty of Health and Medical Science, University of Western Australia, Nedlands, WA, Australia.

Background: Anti-tumor CD8 T cells are important for immunity but can become 'exhausted' and hence ineffective. Tumor-infiltrating exhausted CD8 T cells include less differentiated stem-like exhausted T (Tex) cells and terminally exhausted T (Tex) cells. Both subsets have been proposed as prognostic biomarkers in cancer patients.

View Article and Find Full Text PDF
Article Synopsis
  • Antibodies targeting immune checkpoints like CTLA-4 and PD-1/PD-L1 are used to treat various cancers, often combined with chemotherapy, but the role of other checkpoints like LAG-3 is less understood.
  • * Recent studies showed that chemotherapy increases the presence of specific T cells (both CD4 and CD8) expressing LAG-3 in tumors, suggesting a broader effect on immune response.
  • * Combining anti-LAG-3 and anti-PD-1 therapies with chemotherapy led to significantly better tumor control than using any of the treatments alone, indicating the importance of how chemotherapy changes immune checkpoint expression in treatment strategies.*
View Article and Find Full Text PDF

Background And Objectives: Coronary artery calcification (CAC) is a frequent additional finding on lung cancer screening (LCS) low-dose computed tomography (LDCT). Cardiovascular disease (CVD) is a major cause of death in LCS participants. We aimed to describe prevalence of incidental CAC detected on LDCT in LCS participants without prior history of coronary artery disease (CAD), evaluate their CVD risk and describe subsequent investigation and management.

View Article and Find Full Text PDF

Introduction: The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.

Methods: Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM.

View Article and Find Full Text PDF
Article Synopsis
  • Lung cancer is a major health issue in Australia and New Zealand, with 16,000 new cases annually, and variations in care and outcomes have been noted over the years without established benchmarks.
  • A study utilized a modified eDelphi consensus process to define clinical quality indicators relevant to lung and thoracic cancer care, involving clinicians, patient advocates, and researchers from across the region.
  • Ultimately, 27 clinical quality indicators were agreed upon, aiming to improve the quality of care, with plans for future implementation using real-world data across Australia.
View Article and Find Full Text PDF

Purpose: The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy.

Methods: Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included.

View Article and Find Full Text PDF

Immunotherapy is a rapidly evolving field, with many models attempting to describe its impact on the immune system, especially when paired with radiotherapy. Tumor response to this combination involves a complex spatiotemporal dynamic which makes either clinical or pre-clinical in vivo investigation across the resulting extensive solution space extremely difficult. In this review, several in silico models of the interaction between radiotherapy, immunotherapy, and the patient's immune system are examined.

View Article and Find Full Text PDF
Article Synopsis
  • The International Association for the Study of Lung Cancer created an international database to assess the need for updates to the TNM classification of diffuse pleural mesothelioma (PM) based on clinical and pathologic N categories from 2013 to 2022.
  • After analyzing 3,598 cases, the study found that the existing eighth edition N categories performed adequately, with patients classified as N0 showing better overall survival compared to N1 patients.
  • The results indicate no necessary changes to the N categories for the ninth edition of the PM staging system, as the findings support continuing the current classification.
View Article and Find Full Text PDF

Time-critical transcriptional events in the immune microenvironment are important for response to immune checkpoint blockade (ICB), yet these events are difficult to characterise and remain incompletely understood. Here, we present whole tumor RNA sequencing data in the context of treatment with ICB in murine models of AB1 mesothelioma and Renca renal cell cancer. We sequenced 144 bulk RNAseq samples from these two cancer types across 4 time points prior and after treatment with ICB.

View Article and Find Full Text PDF

This study combines two innovative mouse models in a major gene discovery project to assess the influence of host genetics on asbestos related disease (ARD). Conventional genetics studies provided evidence that some susceptibility to mesothelioma is genetic. However, the identification of host modifier genes, the roles they may play, and whether they contribute to disease susceptibility remain unknown.

View Article and Find Full Text PDF

Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude variation in host genetics, environmental factors and tumour mutation burden, limiting variation between animals to naturally diverse TCRβ repertoires, we applied TCRseq, single cell RNAseq and flow cytometry to study TCRβ repertoire dynamics in ICT responders and non-responders. Increased oligoclonal expansion of TCRβ clonotypes was observed in responding tumours.

View Article and Find Full Text PDF

Introduction: The primary tumor (T) component in the eighth edition of pleural mesothelioma (PM) staging system is based on pleural involvement and extent of invasion. Quantitative assessment of pleural tumor has been found to be prognostic. We explored quantitative and qualitative metrics to develop recommendations for T descriptors in the upcoming ninth edition of the PM staging system.

View Article and Find Full Text PDF

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.

Eur J Cancer

May 2024

Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address:

Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM).

Methods: In this phase 2 open-label trial, patients with PM progressing after first-line chemotherapy were randomised to receive ipilimumab and nivolumab alone (arm B) or combined with UV1 (arm A). The primary endpoint was progression-free survival (PFS) as determined by BICR.

View Article and Find Full Text PDF

Background: Chemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects.

View Article and Find Full Text PDF

Background And Objective: Australia introduced a partial ban on asbestos consumption in 1984. There is continuing concern about exposure to asbestos in the built environment and non-occupational exposures. The aim of this study was to describe epidemiological trends of mesothelioma in Western Australia (WA) over the 60 years since the first case was recorded.

View Article and Find Full Text PDF

Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.

Curr Oncol Rep

December 2023

National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia.

Purpose Of Review: In this article, we provide a comprehensive analysis of recent progress in the genetic characterisation of pleural mesothelioma, and the translation of these findings to clinical practice.

Recent Findings: Advancements in sequencing technology have allowed the identification of driver mutations and improved our understanding of how these mutations may shape the mesothelioma tumour microenvironment. However, the identification of frequently mutated regions including CDKN2A, BAP1 and NF2 have, to date, not yet yielded targeted therapy options that outperform standard chemo- and immunotherapies.

View Article and Find Full Text PDF

International standards of care in thoracic oncology: A narrative review of clinical quality indicators.

Lung Cancer

December 2023

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia; Curtin Medical School, Curtin University, Perth, Australia; National Centre for Asbestos Related Diseases, Institute for Respiratory Health, Perth, Australia. Electronic address:

Unwarranted variations in lung cancer care are widely described. Clinical Quality Indicators (CQIs) enable the systematic identification and alleviation of variations in care and other evidence-practice gaps. The aim of this review was to describe and evaluate lung cancer CQIs utilised internationally, in order to provide a substrate for the development of Australasian lung cancer CQIs and future quality improvement initiatives.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer immunogenomics combines the study of genes and the immune system to learn more about cancer.
  • New technologies allow scientists to look at cancer cells closely and find important changes that could help treat patients.
  • The review talks about different computer methods used to analyze cancer data and how to choose the right tool to help doctors improve cancer treatments for patients.
View Article and Find Full Text PDF

Introduction: Malignant pleural mesothelioma is difficult to prognosticate. F18-Fluorodeoxyglucose positron emission tomography (FDG PET) shows promise for response assessment but is confounded by talc pleurodesis. F18-Fluorothymidine (FLT) PET is an alternative tracer specific for proliferation.

View Article and Find Full Text PDF

New Markers for Management of Mesothelioma.

Semin Respir Crit Care Med

August 2023

National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia.

In this review, we provide an update on the status of cancer biomarkers for the clinical management of pleural mesothelioma, an aggressive cancer associated with asbestos exposure. Mesothelioma can be difficult to diagnose, and response to treatment is transient, even with recently adopted immune checkpoint inhibitor (ICI) combinations. Identification of mesothelioma-specific biomarkers could facilitate early diagnosis and tailor treatment strategies.

View Article and Find Full Text PDF

Mesothelioma is characterised by its aggressive invasive behaviour, affecting the surrounding tissues of the pleura or peritoneum. We compared an invasive pleural model with a non-invasive subcutaneous model of mesothelioma and performed transcriptomic analyses on the tumour samples. Invasive pleural tumours were characterised by a transcriptomic signature enriched for genes associated with MEF2C and MYOCD signaling, muscle differentiation and myogenesis.

View Article and Find Full Text PDF

Background And Objective: Asbestos is a major risk factor for lung cancer, with or without tobacco smoke exposure. Low dose computed tomography (LDCT) screening for early lung cancer is effective but only when targeting high risk populations. This study aimed to analyse the effectiveness of LDCT screening in an asbestos exposed population and to compare lung cancer screening program (LCSP) eligibility criteria.

View Article and Find Full Text PDF